Drug
Atibuclimab
Atibuclimab: highest development phase Phase 1/2, developed by Implicit Bioscience. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Implicit Bioscience
Trials
| Drug | Phase | Indication |
|---|---|---|
| Atibuclimab (IC14), 20 mg/kg intravenously, once NCT06678074 | Phase 1/2 | STEMI |
| Atibuclimab (IC14) NCT06556810 | Phase 1/2 | Acute Decompensated Heart Failure |
Latest
No recent events.
Follow Atibuclimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.